Evidence map›Paper›PMID 42260380›Full record

ArticleBMC cancer2026

Integrating DNA methylation and clinical features to predict prostate cancer prognosis.

Yi Qian, Wei Zhu, Zhenxuan Fang, Zeyu Luo, Wenhua Xie, Yifang Cao, Wei Chen, Huiyu Fu, Jiayu Peng, Lijun Zhang and 7 more

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yi Qian *Tongxiang Hospital of Traditional Chinese Medicine, Jiaxing, 314500, China.
Wei Zhu *Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.
Zhenxuan Fang *Key Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China.
Zeyu LuoZhejiang Chinese Medical University, Hangzhou, 310053, China.
Wenhua Xie *Department of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.
Yifang CaoDepartment of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.
Wei ChenDepartment of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.
Huiyu FuKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China.
Jiayu PengKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China.
Lijun ZhangKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China.
Siyu LeiDepartment of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.
Jing JinDepartment of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China.
Jieyi LiKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China.ORCID http://orcid.org/0000-0003-2881-2281
Xiaokai ZhaoKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China.
Ziying GongKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China. gzy@yunyingmedicine.com.
Daoyun ZhangKey Laboratory of Precision Medicine and Companion Diagnostics, Jiaxing Yunying Medical Inspection Co. Ltd, Jiaxing, 314000, China. zdy@yunyingmedicine.com.
Yi HeDepartment of Urology, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, China. heyi@zjxu.edu.cn.

Funding

Jiaxing Key Laboratory 2020-mnzdsysthe Jiaxing Key Disciplines Project 2023-ZC-013the Key Research and Development Program of Zhejiang province 2023C03057the Key Technology Innovation Projects of Jiaxing 2024BZ20002the Natural Science Foundation of Zhejiang pvovince, China LTGD24H050001the Zhejiang Leading Talent Entrepreneurship Project 2021R02019
6 · The paper itself

Abstract

This study investigates the relationship between DNA methylation patterns and clinicopathological characteristics in prostate cancer. We performed targeted next-generation sequencing (NGS) on methylation sites linked to prostate cancer and calculated the corresponding methylation rates. Clinical samples were divided into training and prediction sets. In the training set, we utilized unsupervised clustering and Support Vector Machine (SVM) modeling to distinguish between prostate cancer and non-cancer samples. For predictions, K-Nearest Neighbors (KNN) assessed sample similarity, while SVM facilitated classification. Bayesian methods integrated probabilities to predict cancer status and cluster assignments. To address uncertainties identified by Uniform Manifold Approximation and Projection (UMAP), we validated our results using Random Forest Support Vector Machine (RFSVM), which highlighted significant methylation sites for SVM training. Depth-correction methods were applied to mitigate variations in sequencing depth.In the training dataset, the leave-one-out cross-validation (LOOCV) prediction accuracy of RFSVM was 0.85 (AUC: 0.91); for RFSVM-depth, it was 0.83 (AUC: 0.93). The LOOCV prediction accuracy for Bayesian SVM (BSVM) was 0.87 (AUC: 0.94), decreasing to 0.83 (AUC: 0.91) with depth correction. In the test dataset, our Bayesian prediction achieved an accuracy of 0.8793 (sensitivity: 0.8182, specificity: 0.9167), which improved to 0.9655 with depth correction (sensitivity: 1.0, specificity: 0.9444). RFSVM demonstrated an accuracy of 0.8621 (sensitivity: 0.8182, specificity: 0.8889), dropping to 0.7759 with depth correction. Among 58 samples, predictions showed 67% complete consistency, with 84% consistency in methylation rates and 78% in specific methylation sites. Figure 6 presents a comprehensive comparison of the performance of RFSVM, BSVM, XBSVM, and RFESVM on training and test datasets, including feature selection and prediction consistency. Confusion matrices, ROC curves, and Venn diagrams were used to detail the feature importance and prediction consistency of each method.These findings highlight the importance of analyzing individual methylation sites and broader methylation patterns in understanding the role of DNA methylation in prostate cancer, providing valuable insights into the effects of data preprocessing and feature selection.

Indexed as

DNA MethylationProstatic NeoplasmsBayes TheoremBiomarkers, TumorClassification AlgorithmsHigh-Throughput Nucleotide SequencingHumansMalePrediction AlgorithmsPrognosisRandom ForestSupport Vector MachineBiomarkers, TumorDepth correctionProstate cancer screeningSVM classificationTargeted DNA methylation sequencingUnsupervised clustering

Identifiers

PMID42260380
PMCPMC13474705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.